These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

525 related items for PubMed ID: 2379154

  • 1. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

  • 2. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D, Sosman JA, Hank JA, Weil-Hillman G, Moore KH, Borchert A, Bechhofer R, Storer B, Kohler PC, Levitt D.
    Cancer Res; 1989 Dec 01; 49(23):6832-9. PubMed ID: 2819723
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 4. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW, Smith JW, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S.
    Cancer Res; 1990 Nov 15; 50(22):7343-50. PubMed ID: 2224862
    [Abstract] [Full Text] [Related]

  • 5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C, García-Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, García-Castellano JM, Torres A.
    Bone Marrow Transplant; 1997 Mar 15; 19(6):545-51. PubMed ID: 9085733
    [Abstract] [Full Text] [Related]

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 7. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF, Hough KL, Holder WD.
    Surgery; 1992 Mar 15; 111(3):326-34. PubMed ID: 1542858
    [Abstract] [Full Text] [Related]

  • 8. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A.
    Cancer Res; 1989 Jan 01; 49(1):235-40. PubMed ID: 2783243
    [Abstract] [Full Text] [Related]

  • 9. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM, Padavic-Shaller K, Kitson J, Watts P, Krigel RL, Litwin S.
    Cancer Res; 1991 Aug 01; 51(15):3910-8. PubMed ID: 1906779
    [Abstract] [Full Text] [Related]

  • 10. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG, Zeuthen J, Claësson MH.
    Nat Immun; 1992 Aug 01; 11(1):7-16. PubMed ID: 1611282
    [Abstract] [Full Text] [Related]

  • 11. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.
    Cancer Res; 1992 Nov 15; 52(22):6318-22. PubMed ID: 1384959
    [Abstract] [Full Text] [Related]

  • 12. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 13. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
    Urba WJ, Steis RG, Longo DL, Kopp WC, Maluish AE, Marcon L, Nelson DL, Stevenson HC, Clark JW.
    Cancer Res; 1990 Jan 01; 50(1):185-92. PubMed ID: 2293554
    [Abstract] [Full Text] [Related]

  • 14. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 01; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 15. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 01; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 17. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J.
    Nat Immun; 1992 Oct 01; 11(3):133-43. PubMed ID: 1392401
    [Abstract] [Full Text] [Related]

  • 18. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM, McKenzie RS, Simms PE, Helfrich BA, Fisher RI.
    J Immunol; 1989 Dec 15; 143(12):4282-6. PubMed ID: 2512355
    [Abstract] [Full Text] [Related]

  • 19. Augmentation of human lymphokine-activated killer cell activity in splenic lymphocytes by the combination of low-dose interleukin 2 plus interleukin 3.
    Okuno K, Ohnishi H, Shilayama Y, Hirohata T, Ozaki M, Yasutomi M.
    Mol Biother; 1992 Jun 15; 4(2):83-6. PubMed ID: 1515099
    [Abstract] [Full Text] [Related]

  • 20. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y, Custer MC, Rosenberg SA, Lotze MT.
    J Immunol; 1989 May 15; 142(10):3452-61. PubMed ID: 2654291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.